[1] Bravo D, Hoare A, Soto C, et al. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects[J]. World J Gastroenterol, 2018, 24(28):3071-3089. [2] 滕贵根, 刘芳勋. 第十五届全国幽门螺杆菌及消化疾病诊治临床论坛暨第四届全国幽门螺杆菌与胃肠微生态中西医整合高峰论坛会议纪要[J]. 中华医学杂志, 2021, 101(2):165-166. [3] Chen L,Xu W,Lee A,et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial[J]. E Bio Medicine, 2018, 35:87-96. [4] Siddique O,Ovalle A,Siddique AS,et al. Helicobacter pylori infection: an update for the internist in the age of increasing global antibiotic resistance[J]. Am J Med, 2018, 131(5):473-479. [5] Leja M,Dumpis U. What would the screen-and-treat strategy for Helicobacter pylori mean in terms of antibiotic consumption[J]. Dig Dis Sci, 2020, 65(6):1632-1642. [6] Jeyamani L, Jayarajan J, Leelakrishnan V, et al. CagA and VacA genes of Helicobacter pylori and their clinical relevance[J]. Indian J Pathol Microbiol, 2018, 61(1):66-69. [7] Nejati S,Karkhah A,Darvish H,et al. Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders[J]. Microb Pathog, 2018, 117(5):43-48. [8] 李兆申, 贝政平, 王琍琳. 消化道疾病诊疗标准[M]. 上海: 上海科学普及出版社, 2014:117-119. [9] 司华. 抗生素的合理应用[M]. 上海市: 上海科学技术出版社, 2015: 92-94. [10] Boyanova L,Hadzhiyski P,Kandilarov N,et al. Multidrug resistance in Helicobacter pylori: current state and future directions[J]. Expert Rev Clin Pharmacol, 2019, 12(9):909-915. [11] Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy[J]. Crit Rev Microbiol, 2018, 44(3):371-392. [12] Capurro MI, Greenfield LK, Prashar A, et al. VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1[J]. Nat Microbiol, 2019, 4(8):1411-1423. [13] Lopo I,Libanio D,Pita I,et al. Helicobacter pylori antibiotic resistance in Portugal: systematic review and meta-analysis[J]. Helicobacter, 2018, 23(4):124-133. [14] Khien VV, Thang DM, Hai TM, et al. Management of antibiotic-resistant Helicobacter pylori infection: perspectives from Vietnam[J]. Gut Liver, 2019, 13(5):483-497. [15] 刘颖, 朱以军, 王月, 等. 浙江金华地区幽门螺杆菌耐药性和耐药基因突变位点分析[J]. 国际流行病学传染病学杂志, 2018, 45(4):242-245. [16] Altobelli A,Bauer M,Velez K,et al. Helicobacter pylori vaca targets myeloid cells in the gastric lamina propria to promote peripherally induced regulatory t-cell differentiation and persistent infection[J]. mBio, 2019, 10(2):261-269. [17] Lee SM, Kim N, Kwon YH, et al. rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: their relation to clinical outcomes[J]. J Gastroenterol Hepatol, 2018, 33(3):681-688. [18] Haddadi MH, Negahdari B, Asadolahi R, et al. Helicobacter pylori antibiotic resistance and correlation with cagA motifs and homB gene[J]. Postgrad Med, 2020, 132(6):512-520. [19] Du J, Zhang W, Li XH, et al. Bioinformatics analysis of small RNAs in Helicobacter pylori and the role of NAT-67 under tinidazole treatment[J]. Mol Med Rep, 2020, 22(2):1227-1234. [20] Salmanroghani H, Mirvakili M, Baghbanian M, et al. Efficacy and tolerability of two quadruple regimens: bismuth, omeprazole, metronidazole with amoxicillin or tetracycline as first-line treatment for eradication of Helicobacter pylori in patients with duodenal ulcer: a randomized clinical trial[J]. PLoS One, 2018, 13(6):197-206. [21] Fagoonee S, Pellicano R. Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review[J]. Infect Dis (Lond), 2019, 51(6):399-408. [22] Chauhan N,Tay ACY,Marshall BJ,et al. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: an overview[J]. Helicobacter, 2019, 24(1):125-134.
2021, Vol. 28 
